Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 96,699
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12617826 | CLEC2 fusion protein and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-09-29 | 0 | 31 |
| 12617831 | Peptide targeting GIP and GLP-2 receptors for treating bone disorders | 🖼🧊📄§ | 2026-05-05 | 2040-02-21 | 0 | 31 |
| 12617833 | Tethered interleukin-15 and interleukin-21 | 🖼🧊📄§ | 2026-05-05 | 2039-02-07 | 0 | 31 |
| 12617832 | Genetic engineering of B cell receptors and uses thereof in antigen-induced antibody secretion | 🖼🧊📄§ | 2026-05-05 | 2041-03-12 | 0 | 31 |
| 12617836 | Tumor environment specific expression of effector genes | 🖼🧊📄§ | 2026-05-05 | 2042-03-21 | 0 | 31 |
| 12617837 | Composition for use in treatment of allergic diseases | 🖼🧊📄§ | 2026-05-05 | 2040-02-28 | 0 | 31 |
| 12617839 | Factor VIII chimeric proteins and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2041-11-05 | 0 | 31 |
| 12617841 | Nucleic acid antibody constructs for use against respiratory syncytial virus | 🖼🧊📄§ | 2026-05-05 | 2039-01-31 | 0 | 31 |
| 12617850 | Treatment of PD-L1-positive melanoma using an anti-PD-1 antibody | 🖼🧊📄§ | 2026-05-05 | 2042-03-22 | 0 | 31 |
| 12617849 | Antigen specific CD19-targeted CAR-T cells | 🖼🧊📄§ | 2026-05-05 | 2040-04-29 | 0 | 31 |
| 12617851 | TREM2 antibodies and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-05-05 | 0 | 31 |
| 12617856 | Protease-cleavable substrates and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2045-03-17 | 0 | 31 |
| 12617867 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | 🖼🧊📄§ | 2026-05-05 | 2039-09-25 | 0 | 31 |
| 12617870 | Methods of reversing ticagrelor activity | 🖼🧊📄§ | 2026-05-05 | 2039-09-20 | 0 | 31 |
| 12617864 | Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof | 🖼🧊📄§ | 2026-05-05 | 2042-04-12 | 0 | 31 |
| 12617866 | Humanized antibodies to mucin-16 and methods of use thereof | 🖼🧊📄§ | 2026-05-05 | 2040-05-07 | 0 | 31 |
| 12616823 | Sustained release formulations in delivery devices | 🖼🧊📄§ | 2026-05-05 | 2039-09-10 | 0 | 31 |
| 12617816 | Composition and method for in vivo assay of opioid receptors | 🖼🧊📄§ | 2026-05-05 | 2040-11-11 | 0 | 31 |
| 12616675 | Antifungal liquid and antifungal gel | 🖼🧊📄§ | 2026-05-05 | 2043-08-04 | 0 | 31 |
| 12616683 | Combination therapy for the treatment of gastrointestinal stromal tumors | 🖼🧊📄§ | 2026-05-05 | 2044-04-10 | 0 | 31 |
| 12616756 | Dimeric antibodies | 🖼🧊📄§ | 2026-05-05 | 2044-08-16 | 0 | 31 |
| 12616704 | Cannabichromene formulation for pain management | 🖼🧊📄§ | 2026-05-05 | 2041-03-31 | 0 | 31 |
| 12616757 | Compositions and methods for correction of heritable ocular disease | 🖼🧊📄§ | 2026-05-05 | 2041-04-14 | 0 | 31 |
| 12617835 | Chimeric autoantibody receptor (CAAR) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease | 🖼🧊📄§ | 2026-05-05 | 2040-06-05 | 0 | 31 |
| 12616668 | Nutritional supplement containing L-α-glycerophosphorylcholine | 🖼🧊📄§ | 2026-05-05 | 2044-01-22 | 0 | 31 |
| 12616664 | Myo-inositol and the prevention of preterm birth | 🖼🧊📄§ | 2026-05-05 | 2040-08-21 | 0 | 31 |
| 12616666 | Coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa | 🖼🧊📄§ | 2026-05-05 | 2042-07-13 | 0 | 31 |
| 12616669 | Methods and chemical compositions for treating skin conditions by providing long lasting skin pH control for improving skin barrier function | 🖼🧊📄§ | 2026-05-05 | 2045-08-27 | 0 | 31 |
| 12616660 | Compressible and free-flow co-agglomerates of crystalline mannitol and granular starch | 🖼🧊📄§ | 2026-05-05 | 2041-09-24 | 0 | 31 |
| 12616658 | Method for preparation of liposomes | 🖼🧊📄§ | 2026-05-05 | 2041-07-01 | 0 | 31 |
| 12616659 | Therapeutic agent nanoparticles and methods of preparation | 🖼🧊📄§ | 2026-05-05 | 2043-05-24 | 0 | 31 |
| 12616655 | Topical antibiotic containing pharmaceutical composition for bacterial infections and wound healing | 🖼🧊📄§ | 2026-05-05 | 2040-10-19 | 0 | 31 |
| 12616657 | Cell-targeted nanoparticles to inhibit RNA cargo | 🖼🧊📄§ | 2026-05-05 | 2041-02-26 | 0 | 31 |
| 12616644 | Polyurethane gels | 🖼🧊📄§ | 2026-05-05 | 2040-07-10 | 0 | 31 |
| 12616647 | Non-pulverulent antisun composition comprising a polar oil phase and hydrophobic silica aerogel particles | 🖼🧊📄§ | 2026-05-05 | 2044-02-01 | 0 | 31 |
| 12616648 | Cosmetic composition | 🖼🧊📄§ | 2026-05-05 | 2039-04-08 | 0 | 31 |
| 12616651 | Topical lipolysis composition and methods | 🖼🧊📄§ | 2026-05-05 | 2041-10-07 | 0 | 31 |
| 12616650 | Radiation sensitizer of anti-cancer chemotherapy sensitizer | 🖼🧊📄§ | 2026-05-05 | 2040-07-23 | 0 | 31 |
| 12616653 | Solid orodispersible pharmaceutical composition in film containing lorazepam | 🖼🧊📄§ | 2026-05-05 | 2042-03-01 | 0 | 31 |
| 12616649 | Composition containing plant extracts | 🖼🧊📄§ | 2026-05-05 | 2041-01-04 | 0 | 31 |
| 12616747 | Stabilized beta-coronavirus antigens | 🖼🧊📄§ | 2026-05-05 | 2042-12-02 | 0 | 31 |
| 12616727 | Compositions, systems, and methods for improving health | 🖼🧊📄§ | 2026-05-05 | 2043-06-29 | 0 | 31 |
| 12616726 | Probiotic supplement for metabolic health | 🖼🧊📄§ | 2026-05-05 | 2044-03-27 | 0 | 31 |
| 12616712 | Sting agonist comprising exosomes for treating neuroimmunological disorders | 🖼🧊📄§ | 2026-05-05 | 2040-09-24 | 0 | 31 |
| 12616701 | Solid state forms of Resmetirom | 🖼🧊📄§ | 2026-05-05 | 2041-10-19 | 0 | 31 |
| 12616693 | Bromocriptine formulations | 🖼🧊📄§ | 2026-05-05 | 2043-04-26 | 0 | 31 |
| 12616692 | Method of achieving HIV viral remission using long-acting antiretroviral agents | 🖼🧊📄§ | 2026-05-05 | 2041-06-30 | 0 | 31 |
| 12616671 | Use of rigosertib to treat RNA virus infections | 🖼🧊📄§ | 2026-05-05 | 2041-05-28 | 0 | 31 |
| 12618031 | Delivery devices | 🖼🧊📄§ | 2026-05-05 | 2041-06-24 | 0 | 31 |
| 12618048 | Dual CAR-T cells | 🖼🧊📄§ | 2026-05-05 | 2041-07-30 | 0 | 31 |